Summary
The plasma concentrations and urinary excretion of paracetamol and its glucuronide, sulphate, cysteine and mercapturic acid conjugates were measured in eight normal subjects, eight patients with mild liver disease and seven patients with severe liver disease following an oral dose of 1.5 g of paracetamol. The mean plasma paracetamol half-life was similar in normal subjects (2.43 h±0.19) and those with mild liver disease (2.16 h±0.54) but was significantly prolonged in all patients with severe liver disease (4.25 h±1.15:p=<0.001). Prolongation of the paracetamol half-life was related to reduced plasma albumin and increased prothrombin time. The mean ratios of plasma concentrations of unchanged paracetamol to paracetamol glucuronide and sulphate were significantly greater in patients with severe liver disease than the normal subjects. There were no significant differences in the overall 24-h urinary excretion of paracetamol and its glucuronide, sulphate, cysteine and mercapturic acid conjugates in the three groups. The glutathione conjugation of paracetamol did not seem to be impaired in patients with severe liver disease as evidenced by the production of normal amounts of the cysteine and mercapturic acid conjugates. There is thus no evidence that they are at increased risk of hepatotoxicity when given a single therapeutic dose of paracetamol.
Similar content being viewed by others
References
Proudfoot, A.T., Wright, N.: Acute paracetamol poisoning. Br. Med. J.1970/III, 557–558
Prescott, L.F., Wright, N., Roscoe, P., Brown, S.S.: Plasma paracetamol half-life and hepatic necrosis in patients with paracetamol overdosage. Lancet1971/I, 519–522
Clark, R., Thompson, R.P.H., Borirakehanyavat, U., Widdop, S., Davidson, A.R., Goulding, R., Williams, R.: Hepatic damage and death from overdose of paracetamol. Lancet1973/I, 66–69
Mitchell, J.R., Jollow, D.J., Potter, W.Z., Davis, D.C., Gillette, J.R., Brodie, B.B.: Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J. Pharmacol. Exp. Ther.187, 185–194 (1973)
Jollow, D.J., Mitchell, J.R., Potter, W.Z., Davis, D.C., Gillette, J.R., Brodie, B.B.: Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. J. Pharmacol. Exp. Ther.187, 195–202 (1973)
Potter, W.Z., Davis, D.C., Mitchell, J.R., Jollow, D.J., Gillette, J.R., Brodie, B.B.: Acetaminophen-induced hepatic necrosis. III. Cytochrome P-450 mediated covalent binding in vitro. J. Pharmacol. Exp. Ther.187, 203–210 (1973)
Mitchell, J.R., Jollow, D.J., Potter, W.Z., Gillette, J.R., Brodie, B.B.: Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J. Pharmacol. Exp. Ther.187, 211–217 (1973)
Fevery, J., de Groote, J.: Conjugation of N-acetyl-p-aminophenol (N.A.P.A.) in adult liver patients. Acta Hepato-Splenol.16, 11–18 (1969)
Shamszad, M., Soloman, H., Mobarhan, S., Iber, F.L.: Abnormal metabolism of acetaminophen in patients with alcoholic liver disease. Gastroenterology69, 865 (1975)
Forrest, J.A.H., Finlayson, N.D.C., Adjepon-Yamoah, K.K., Prescott, L.F.: Antipyrine, paracetamol, and lignocaine elimination in chronic liver disease. Br. Med. J.1977/I, 1384–1387
Howie, D., Adriaenssens, P.I., Prescott, L.F.: Paracetamol metabolism following overdosage: application of high performance liquid chromatography. J. Pharm. Pharmacol.29, 235–237 (1977)
Triggs, E.J., Nation, R.L., Long, A., Ashley, J.J.: Pharmacokinetics in the elderly. Europ. J. Clin. Pharmacol.8, 55–62 (1975)
Davis, M., Simmons, C.J., Harrison, N.G., Williams, R.: Paracetamol overdose in man: Relationship between pattern of urinary metabolites and severity of liver damage. Quart. J. Med.178, 181–191 (1976)
Barker, J.D., de Carle, D.J., Anuras, S.: Chronic excessive acetaminophen use and liver damage. Ann. Intern. Med.87, 299–301 (1977)
Johnson, G.K., Tolman, K.G.: Chronic liver disease and acetaminophen. Ann. Intern. Med.87, 302–304 (1977)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Forrest, J.A.H., Adriaenssens, P., Finlayson, N.D.C. et al. Paracetamol metabolism in chronic liver disease. Eur J Clin Pharmacol 15, 427–431 (1979). https://doi.org/10.1007/BF00561743
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00561743